2021 is a year in which there are great expectations. Society is confident that the arrival of the vaccine will ease the restrictions of the countries and that day-to-day life is becoming more and more like what it was in February 2020. Although, without a doubt, the ones that have caught the new year with the greatest enthusiasm they are big pharma.
The massive sale of vaccines to countries around the world will generate significant revenue for Pfizer-BioNTech and Moderna, the most advanced companies in the race for immunity. According to data provided by Finaria, the sales of the vaccine against Covid-19 will represent the three groups revenue of $ 14.7 billion over the next three years.
The Pfizer-BioNTech drug was the first to start shipping. The cooperation between the two pharmaceutical companies will generate revenues of 3.1 billion dollars in 2021. However, the experts emphasize that this figure will decrease in the coming years. This drug is at a disadvantage compared to its competitors. It needs temperatures of about 70 degrees below zero to be properly stored.
Moderna is going to be the most benefited from this situation. Your medicine does not need such low temperatures which will lead countries to opt for its doses, its transport and storage is easier. In the next 12 months Moderna will pocket about 3,500 million, a figure 400 million higher than that of the Pfizer-BioNTech tandem. Contrary to what will happen with the last two, Moderna's income will remain stable over time.
Both Pfizer-BioNTech and Moderna are focused on producing the drug against Covid-19. So much so that the former have reported that they are going to cut their vaccine shipments to Europe for a time. The objective is none other than to increase production.
"Although this will temporarily affect shipments from late January to early February, will provide a significant increase in doses available to patients at the end of February and March, "the company detailed in a statement.